Hsbc Holdings PLC Acquires 37,610 Shares of Xencor, Inc. $XNCR

Hsbc Holdings PLC lifted its holdings in Xencor, Inc. (NASDAQ:XNCR) by 179.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 58,579 shares of the biopharmaceutical company’s stock after buying an additional 37,610 shares during the quarter. Hsbc Holdings PLC’s holdings in Xencor were worth $717,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. BVF Inc. IL raised its holdings in Xencor by 160.3% during the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after buying an additional 4,393,579 shares during the period. Legal & General Group Plc boosted its holdings in shares of Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after buying an additional 1,092,095 shares during the period. State Street Corp boosted its holdings in shares of Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after buying an additional 833,423 shares during the period. Jefferies Financial Group Inc. increased its position in shares of Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after acquiring an additional 620,440 shares in the last quarter. Finally, RTW Investments LP increased its position in shares of Xencor by 8.9% during the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after acquiring an additional 556,407 shares in the last quarter.

Xencor Stock Up 10.0%

NASDAQ XNCR opened at $21.49 on Friday. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $21.76. The company has a market capitalization of $1.59 billion, a PE ratio of -9.38 and a beta of 0.86. The firm’s 50 day moving average is $14.69 and its 200-day moving average is $13.10.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The business had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business’s revenue for the quarter was down 86.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.66) EPS. As a group, sell-side analysts expect that Xencor, Inc. will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

XNCR has been the topic of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research report on Thursday. Wall Street Zen cut Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Truist Financial cut their price target on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. upped their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average price target of $24.25.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.